Home > Analytics > LINCOLN PHARMACEUTICALS

LINCOLN PHARMACEUTICALS
Intrinsic Value | Fundamental Analysis

BOM : 531633     NSE : LINCOLN    
LT :  
    Long Term Analysis
Fundamentals : Good
Valuation : Bad [Stock is Expensive]
Debt : Low
Updated:
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Neutral
Price Momentum : Downward
Pledged Shares : None or < 25%
May 24,2024
Price(EOD): ₹ 566.50
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
Pharmaceuticals & Drugs
MCap: ₹ 1,133.00 Cr
Value of ₹ 1 Lac invested in LINCOLN PHARMACEUTICALS
on May 27,2019 (price: ₹ 200.05)

₹ 1 L

₹ 2.83 L

1W : -2% 1M : -4.5% 1Y : 32.4%
COMMUNITY POLL
for LINCOLN PHARMACEUTICALS
Please provide your vote to see the results
LINCOLN PHARMACEUTICALS is part of below Screeners ↓
Top Small Cap Stocks with Best Fundamentals
Industry Peers & Returns1W1M1Y
LINCOLN PHARMACEUTICALS -2% -4.5% 32.4%
SUN PHARMACEUTICAL INDUSTRIES -2.9% 0% 59.6%
CIPLA 5.8% 6.2% 60.9%
DR REDDYS LABORATORIES 0.9% -1.5% 32.2%
ZYDUS LIFESCIENCES -2.6% 15.3% 114.4%
DIVIS LABORATORIES 5% 8% 25.9%
MANKIND PHARMA -2.3% -14% 57.7%
TORRENT PHARMACEUTICALS -3.4% -2.7% 61.2%
LUPIN -2.8% 2.1% 110.5%

FUNDAMENTAL ANALYSIS OF LINCOLN PHARMACEUTICALS

 
Fundamentals Score
[ Q(TTM): Mar2024, Y: Mar2023
Q : Last Qtr data
Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
]

Insights 💡 LINCOLN is one of the top 35% companies with good fundamentals ! Discover More →

VALUATION OF LINCOLN PHARMACEUTICALS

 
Valuation Score
[As on : May 24,2024 ]

Ratio Consolidated
P/E
P/B
P/S
12.16
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 93.30 Cr
[Latest Qtr - Mar2024 - Consolidated Results ]

1.91
P/B Calculated based on Book Value of Rs 592.84 Cr
[Latest Year - Mar2024 - Consolidated Results ]

1.95
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 580.55 Cr
[Latest Qtr - Mar2024 - Consolidated Results ]

Financial Ratios →

Insights 💡 There are potential 12% undervalued companies ! Discover More →

FAIR VALUE OF LINCOLN PHARMACEUTICALS

 
Model Discount(-)/
Premium(+)
EV/EBIDTA
EV/Sales
Price/Sales
88%
38%
48%

Insights 💡 You can learn about various Valuation techniques to calculate Intrinsic Value
with our bestselling video course Value Investing - The Ultimate Guide
Take Me There →

SHARE PRICE MOMENTUM OF LINCOLN PHARMACEUTICALS



LINCOLN PHARMACEUTICALS vs SENSEX


Insights 💡 You can learn about Basics of Stock Marketing Investing
with our bestselling video course Stock Marketing Investing Simplified
Take Me There →

DEBT OF LINCOLN PHARMACEUTICALS

Year Debt/Equity ratio
Standalone Consolidated
2023
2022
2021
Avg_3yrs
0
0
0
-
0
0
0
-
[Last Annual Data : Mar2023]
Financial Ratios →

PLEDGED PROMOTER SHARES OF LINCOLN PHARMACEUTICALS

Pledged Promoter Shares
0 %
As on : Dec2023

If less than 25%

Good
If between 25% and 50% Neutral
If greater than 50% Bad
Shareholding Pattern →

QTRLY RESULTS OF LINCOLN PHARMACEUTICALS

Consolidated Q-o-Q Y-o-Y
Revenue
Op Profit
Profit Before Tax
Profit After Tax
-2.7%
-38.02%
-41.08%
-33.67%
26.71%
10.47%
30.86%
48.04%
QtrlyTrend
0
Latest Qtr: Mar2024
Quarterly Result Analysis →


LINCOLN PHARMACEUTICALS related INDICES

BSE Indices1W1M1Y
S&P BSE ALLCAP 1.9% 3.9% 40.2%
S&P BSE MIDSMALLCAP 1.2% 5.1% 63.7%
S&P BSE SMALL CAP 0.9% 3.2% 61.3%
S&P BSE HEALTHCARE -0% 2.5% 55.6%
No NSE index found

You may also like the below Video Courses


FAQ about LINCOLN PHARMACEUTICALS


Is LINCOLN PHARMACEUTICALS good for long term investment?

As on May 24,2024, the Fundamentals of LINCOLN PHARMACEUTICALS look Strong and hence it may be good for long term investment! See Financial Performance of LINCOLN PHARMACEUTICALS . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!

Is LINCOLN PHARMACEUTICALS UnderValued or OverValued?

As on May 24,2024, LINCOLN PHARMACEUTICALS is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!

What is the Intrinsic Value of LINCOLN PHARMACEUTICALS ?

As on May 24,2024, the Intrinsic Value of LINCOLN PHARMACEUTICALS is Rs. 383.60 estimated based on Median of the 3 historical models.
Fair Value [Median EV / EBIDTA Model] : Rs. 301.62
Fair Value [Median EV / Sales Model] : Rs. 409.82
Fair Value [Median Price / Sales Model] : Rs. 383.60
Estimated Median Fair Value of LINCOLN PHARMACEUTICALS : Rs. 383.60

The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.

Is LINCOLN PHARMACEUTICALS trading at a Premium or Discount?

As on May 24,2024, LINCOLN PHARMACEUTICALS is trading at a Premium of 48% based on the estimates of Median Intrinsic Value!